Supplemental material

	Location	Recruitment	N	Female (%)	Age (years)	Respiratory diseases assessed	Assessment method for respiratory diseases			
Ref.							COPD	Bronchiectasis	Asthma	PFT
29	TEHS	Retrospective review of adult AP referred to the sleep specialist/outreach team with OSA (2011-2015)	297	48.2	48±12.5	COPD	EMR	-	-	-
14	TEHS	Retrospective review of adult AP with a diagnosis of COPD referred to the respiratory outreach team (2012-2016)	380	55.8	57.3±13.2	COPD Bronchiectasis Asthma	EMR	EMR	EMR	Acceptable spirometry in 175 AP
30	TEHS	Retrospective review of adult AP with a diagnosis of COPD and with chest radiology available referred to the respiratory outreach team (2012-2016)	258	49.6	58.4±12.1	COPD Bronchiectasis Asthma	EMR	Radiological evidence	EMR	Acceptable spirometry in 122 AP
7	TEHS	Retrospective review of adult patients diagnosed with bronchiectasis (2012-2017)	388 total: 258 Aboriginal	59.3	54±14.9	COPD Bronchiectasis Asthma	EMR	Radiological evidence, or those hospitalised with ICD code J4713	EMR	Acceptable spirometry in 161 patients (does not specify Aboriginal numbers)
15	TEHS	Retrospective review of adult AP referred to respiratory outreach team (2013-2015)	357	58.2	49±12.9	COPD Bronchiectasis Asthma	GOLD stage 2 or higher	EMR	EMR	Acceptable spirometry in 150 AP
31	TEHS	Retrospective review of adult patients referred to the respiratory specialist/outreach team with acceptable spirometry who had an FEV <sub>1</sub> /FVC ratio <0.7 (2012-2020)	1113 total: 240 Aboriginal	47	54.7±13.64	COPD	FEV <sub>1</sub> /FVC ratio <0.7	-	-	Acceptable spirometry in 240 AP
32	TEHS	Retrospective review of adult AP referred to the respiratory specialist/outreach team with acceptable spirometry who had an FEV <sub>1</sub> /FVC ratio <0.7 or FEV <sub>1</sub> /FVC ratio <lln (2012-2020)<="" td=""><td>253</td><td>47</td><td>54.7±13.63</td><td>COPD Bronchiectasis</td><td>FEV<sub>1</sub>/FVC ratio &lt;0.7 or FEV<sub>1</sub>/FVC ratio <lln< td=""><td>Radiology evidence</td><td>-</td><td>Acceptable spirometry in 253 AP</td></lln<></td></lln>	253	47	54.7±13.63	COPD Bronchiectasis	FEV <sub>1</sub> /FVC ratio <0.7 or FEV <sub>1</sub> /FVC ratio <lln< td=""><td>Radiology evidence</td><td>-</td><td>Acceptable spirometry in 253 AP</td></lln<>	Radiology evidence	-	Acceptable spirometry in 253 AP
33	TEHS	Retrospective review of adult AP referred to the respiratory specialist/outreach team at least twice, with acceptable spirometry performed at both times (2012-2020)	115	50.4	50.4±11.1	COPD Bronchiectasis	Radiology evidence	Radiology evidence	-	Acceptable spirometry in 115 AP
34	TEHS	Retrospective review of adult AP referred to the respiratory specialist/outreach team with Chest CT or Chest X-ray available which showed either chronic lung disease, or no chronic lung disease and had acceptable spirometry (2012-2020)	485	55.8	50.9±16.5	COPD Bronchiectasis	Radiology evidence	Radiology evidence	-	Acceptable spirometry in 485 AP
35	TEHS	Retrospective review of adult patients referred to the respiratory specialist/outreach team with acceptable spirometry (2012-2020)	5321 total: 742 Aboriginal	56.9	50.7±12.6	COPD Bronchiectasis Asthma	Radiology evidence or FEV <sub>1</sub> /FVC < 0.7	Radiology evidence	BDR (12% and 200ml change or 10% change)	Acceptable spirometry in 742 AP
36	TEHS	Retrospective review of adult AP referred to the respiratory specialist/outreach team with Chest CT available (2012-2020)	402	59	53.5±40.8	COPD Bronchiectasis	CT evidence	CT evidence	-	-
37	TEHS	Retrospective review of adult AP referred to the respiratory specialist/outreach team with Chest	212	54.3	53.1±12.2	COPD Bronchiectasis	CT evidence	CT evidence	-	Acceptable spirometry in 212 AP

		CT available which showed either chronic lung disease, or no chronic lung disease and had acceptable spirometry (2012-2020)								
38	TEHS	Retrospective review of adult patients actively receiving DOT (2018-2020)	212 total: 45 Aboriginal	38	61±12.4	COPD Bronchiectasis	EMR	EMR	-	-
39	TEHS	Convenience survey of patients currently hospitalised with, or hospitalised previously with and presenting to respiratory team, an exacerbation of COPD (2020-2021)	86 total: 59 Aboriginal	53	56.3±9.8	COPD Bronchiectasis Asthma	ICD coded hospitalisation	EMR	EMR	Acceptable spirometry in 53 AP
40	TEHS	Retrospective cohort study of adult patients admitted to hospital with a diagnosis of hypomagnesemia (2008-2014)	876 total: 494 Aboriginal	56.1	43.8±16.9	COPD Asthma	EMR	-	EMR	-
41	Central AU	Retrospective review of adult AP (≥15 years) who presented to ASH and had a HTLV-1 screening test (2000-2010)	1451 HTLV-1 + <sup>ve</sup> 507 HTLV-1 - <sup>ve</sup> 944	55.3	HTLV-1 + <sup>ve</sup> : 47.7±13.9 HTLV-1 - <sup>ve</sup> : 43.9±16.6	COPD Bronchiectasis Asthma	EMR	ICD-10 coding Definite – confirmed by HRCT. Possible – no HRCT recorded	EMR	-
8	Central AU	Retrospective review of adult patients (≥15 years) whom had a discharge diagnosis of bronchiectasis via ASH (Aboriginal Australian), MMC (non-Aboriginal Australian) or MH (Māori, Pacific Islanders and non-Aboriginal New Zealanders) (2004-2008)	406 total: 85 Aboriginal	42.4	43.7±12.3	Bronchiectasis	-	HRCT	-	Acceptable spirometry in 54% of AP
42	Central AU	Case-control study of adult AP (≥15 years) who were admitted to ASH with a blood culture pathogen isolated (case) or admitted without infection to surgical or renal units, or for cardiac investigation and were positive for HTLV-1 (2008-2009)	74 44 cases 30 controls	57	Case: 51.3±12.3 Control: 47.2±10.1	COPD Bronchiectasis	EMR	EMR	-	-
43	Central AU	Retrospective review of adult AP (≥15 years) who presented to ASH with an infective exacerbation of bronchiectasis (case) or for a non-respiratory reason with no evidence of LRTI (control) and had a HTLV-1 screening test (2008-2010)	72	30.6	Case: 43.5±71.4 Control: 46.1±75.6	COPD Bronchiectasis Asthma	EMR	HRCT, bronchoscopy and/or bronchography	EMR	-
44	Central AU	Retrospective review of adult AP (≥15 years) who presented to ASH with a discharge diagnosis of bronchiectasis (case) or for a non-respiratory reason with no evidence of LRTI (control) and had a HTLV-1 screening test (2008-2013)	840	42.6	No HTLV-1: 46.2±15.3 Low HTLV-1 PVL: 51.6±13.7 High HTLV-1 PVL: 51.1±13.8	COPD Bronchiectasis	EMR and radiological evidence	HRCT	-	-
45	Central AU	Retrospective review of adult AP (≥18 years) who presented to ASH with a diagnosis of bronchiectasis (case) or for a non-respiratory reason with no history of CLD (control) and had a HTLV-1 screening test (2010-2013)	240	40	-	COPD Bronchiectasis Asthma	EMR and radiological evidence	HRCT	EMR and BDR	-
46	Central AU	Community based survey of seven remote Aboriginal communities including all Aboriginal community members aged >2,	415	54.7	Female HTLV-1 + ve: 44.6±14.5 Female HTLV-1 - ve:	Bronchiectasis	-	HRCT	-	-

Supplemental material

57	SA	Retrospective review of patients on warfarin anticoagulation therapy identified from clinical and administrative databases at the RAH (1999-2012)	512 total: 88 Aboriginal	46.6	51±13	COPD	EMR	-	-	-
8	Victoria	State-wide phone survey of randomly selected adults (2008)	34168 total: 339 Aboriginal	-	-	Asthma	-	-	Self-reported if the patient had in the last 12 months, or ever in the past been diagnosed with asthma by a doctor.	-
9	NSW	Quasi experimental study of AP adults (> 45 years) eligible for registering for the 'Closing the Gap' co-payment incentive and linked data from the "45 and Up Study" (2006-2014)	1,948	56.9	Registered: 56±7.8 Unregistered: 58.3±9.3	Asthma	-	-	Self-reported if the participant has ever been told they have asthma by a doctor.	-
0	Australia	Observational time trend study of Aboriginal adults (>15 years) presenting to hospital with asthma, COPD, hypertension, heart failure or other cardiovascular event in selected pharmaceutical benefits scheme sentinel regions (2009-2011)	Recorded hospital presentations 109583 total: 4596 Aboriginal	-	-	COPD Asthma	ICD coded hospital admissions	-	ICD coded hospital admissions	-
I	Australia	Retrospective review of Adult AP involved in the Kanyini Guidelines Adherence with the polypill randomised controlled trial recruited from 33 primary healthcare centres across Australia (2009-2013)  G. Australian refined diagnosis related groups: ASH.	535 total: 249 Aboriginal	42.2	Urban/regional: 57±8.8 Remote: 55±13.6	COPD	Not stated	-	-	-

Abbreviations: AR-DRG, Australian refined diagnosis related groups; ASH, Alice Springs Hospital; AU, Australia; BDR, Bronchodilator response; COPD, Chronic obstructive pulmonary disease; CT, Computed tomography; DOT, Domiciliary oxygen therapy; EMR, Electronic medical record; FEV<sub>1</sub>, Forced expiratory volume in one second; FVC, Forced vital capacity; GOLD, Global initiative for chronic obstructive lung disease; HRCT, High resolution computed tomography; HTLV-1, Human T-Lymphotropic Virus type 1; ICD, International classification of disease coding; ICPC, International classification of primary care; AP, Aboriginal patients; LLN, Lower limit of normal; MH, Middlemore hospital; MMC, Monash medical centre; LRTI, Lower tract respiratory infection; MMH, Mater mothers hospital; N. QLD, North Queensland; OSA, Obstructive sleep apnoea; PFT, Pulmonary function test; PVL, Proviral load; RAH, Royal Adelaide hospital; Ref., Reference; SA, South Australia; S. QLD, South Queensland; TEHS, Top end health service; WA, Western Australia

Supplemental 3. Outline of studies included for analysis